News

Axillary radiation halves lymphedema rate vs. ALND for breast cancer


 

AT THE ASCO ANNUAL MEETING 2013

The groups were statistically indistinguishable in estimated 5-year rates of overall survival, at about 93%, and disease-free survival, at about 85%.

The 5-year rate of lymphedema – defined in the study as the need for treatment with a sleeve garment, compression therapy, or lymph drainage therapy, or presence of the condition on physical examination – was 28% with ALND and 14% with axillary radiation therapy (P less than .0001), according to Dr. Rutgers.

"The side effects of radiotherapy cannot be neglected but are limited," he commented. "We looked at many other potential side effects of radiotherapy. There was no excess of cardiac problems, a very small excess of radiation pneumonitis; there was no effect on the brachial nerves."

The groups did not differ with respect to overall quality of life, but there were trends toward greater difficulty moving the arm after radiation therapy and greater swelling after ALND.

Dr. Rutgers disclosed no conflicts of interest related to the research.

Pages

Recommended Reading

Oral HPV-related cancer risk not transmitted to sex partners
MDedge Hematology and Oncology
Maintenance pazopanib delays progression of advanced ovarian cancer
MDedge Hematology and Oncology
Cervical cancer screening with acetic acid saves lives
MDedge Hematology and Oncology
Bevacizumab plus chemotherapy extends cervical cancer survival
MDedge Hematology and Oncology
10 years of tamoxifen halves risk of death from breast cancer
MDedge Hematology and Oncology
Which paclitaxel schedule works best for breast cancer?
MDedge Hematology and Oncology
Palbociclib continues on fast track to potential FDA approval
MDedge Hematology and Oncology
Study confirms benefits of 10 years of tamoxifen
MDedge Hematology and Oncology
Weekly adjuvant paclitaxel for breast cancer has less toxicity
MDedge Hematology and Oncology
ASCO 2013: Breast cancer research highlights
MDedge Hematology and Oncology